13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002054410
Total reported value
$366.5M
$366.5M
22 檔
68.4%
According to the latest 13F quarterly dataset, Acorn Capital Advisors, LLC managed an equity portfolio of $366.5M at the end of Q1 2026, spanning 22 distinct U.S. exchange-listed positions.
Acorn Capital Advisors, LLC executed strategic sector rebalancing during Q1 2026, establishing 2 new positions while fully exiting 1 holdings and trimming 6 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 26.17% | -26.17% | EXIT | |
| 2 | CGON | Cg Oncology Inc | Stock-Other | 21.77% | +0.17% | -0.09% | |
| 3 | URGN | UroGen Pharma Ltd. | Stock-Other | 8.55% | +8.25% | +15.53% | |
| 4 | PBYI | Puma Biotechnology Inc | Stock-Other | 7.50% | +1.64% | — | |
| 5 | TRVI | Trevi Therapeutics Inc | Stock-Other | 7.27% | +3.65% | — | |
| 6 | CADL | Candel Therapeutics Inc | Stock-Other | 4.89% | +4.94% | +35.55% | |
| 7 | BCAX | Bicara Therapeutics Inc | Stock-Other | 3.64% | +1.57% | — | |
| 8 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 3.34% | +0.19% | — | |
| 9 | JBIO | Jade Biosciences Inc | Stock-Other | 3.14% | +2.84% | — | |
| 10 | TARA | Protara Therapeutic Inc | Stock-Other | 2.59% | -0.76% | — | |
| 11 | VSTM | Verastem Inc | Stock-Other | 2.21% | -0.68% | — | |
| 12 | HELP | Cybin Inc | Stock-Other | 2.10% | +0.68% | -2.08% | |
| 13 | LONA | Leonabio Inc | Stock-Other | 1.85% | -0.26% | +26.47% | |
| 14 | AURA | Aura Biosciences Inc | Stock-Other | 1.13% | +0.67% | — | |
| 15 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 1.12% | +0.30% | — | |
| 16 | CRDF | Cardiff Oncology Inc | Stock-Other | 0.81% | -0.81% | EXIT | |
| 17 | QTTB | Q32 Bio Inc | Stock-Other | 0.57% | +0.18% | -36.15% | |
| 18 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.46% | +3.59% | — | |
| 19 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.35% | -0.19% | -20.99% | |
| 20 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.27% | -0.27% | EXIT | |
| 21 | BCABGBP | Bioatla Inc | Stock-Other | 0.25% | -0.13% | +11.81% | |
| 22 | VYNE | Vyne Therapeutics Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | +5.9% | -0.09% | Trim |
| 2 | 430 | Terns Pharmaceuticals Inc | +2.3% | — | Unchanged |
| 3 | LONA | Leonabio Inc | +0.6% | +26.47% | Add |
| 4 | OKUR | Onkure Therapeutics Inc-a | +0.6% | — | Unchanged |
| 5 | WHWK | Whitehawk Therapeutics Inc | +0.2% | — | Unchanged |
| 6 | AURA | Aura Biosciences Inc | 0% | — | Unchanged |
| 7 | QTTB | Q32 Bio Inc | 0% | -36.15% | Trim |
| 8 | VYNE | Vyne Therapeutics Inc | — | — | Unchanged |
| 9 | BCAX | Bicara Therapeutics Inc | 0% | — | Unchanged |
| 10 | CADL | Candel Therapeutics Inc | -0.1% | +35.55% | Add |
| 11 | ASNSUSD | X4 Pharmaceuticals Inc | -0.1% | -14.38% | Trim |
| 12 | TARA | Protara Therapeutic Inc | -0.6% | — | Unchanged |
| 13 | BCABGBP | Bioatla Inc | -0.7% | +11.81% | Add |
| 14 | JSPR | Jasper Therapeutics Inc | -0.8% | -20.99% | Trim |
| 15 | PBYI | Puma Biotechnology Inc | -0.8% | — | Unchanged |
| 16 | CRDF | Cardiff Oncology Inc | -1.1% | -10.19% | Trim |
| 17 | VSTM | Verastem Inc | -1.6% | — | Unchanged |
| 18 | TRVI | Trevi Therapeutics Inc | -1.8% | — | Unchanged |
| 19 | HELP | Cybin Inc | -2.3% | -2.08% | Trim |
| 20 | URGN | UroGen Pharma Ltd. | -2.9% | +15.53% | Add |
| 21 | JBIO | Jade Biosciences Inc | — | NEW | New buy |
| 22 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
| 23 | ACRV | Acrivon Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Acorn Capital Advisors, LLC reported a total U.S. public equity portfolio value of $366.5M across 22 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, CGON, URGN) accounted for 68.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
JBIO
市值: $11.1M
Top Position Liquidated / Trimmed
ACRV
前期市值: $976.6K
During Q1 2026, Acorn Capital Advisors, LLC's top holdings by market value included 430 (26.2%)、CGON (21.8%)、URGN (8.6%). The largest single position, 430, represented 26.2% of total portfolio value.
In Q1 2026, Acorn Capital Advisors, LLC made 13 total portfolio adjustments, initiating 2 new buys, adding to 4 positions, trimming 6 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.